Stocktoria
Progyny, Inc. PGNY
Progyny, Inc. (PGNY) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.3B at a 4.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.44 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-22 | Truist Securities | Buy (main) |
| 2026-06-02 | B of A Securities | Buy (main) |
| 2026-05-19 | Canaccord Genuity | Buy (up) |
| 2026-05-18 | Barclays | Overweight (main) |
| 2026-05-11 | Truist Securities | Buy (main) |
| 2026-05-11 | Citizens | Market Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.471 |
| Retained earnings / assets | 0.273 |
| EBIT / assets | 0.115 |
| Equity / liabilities | 2.279 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
| NIVF | NewGenIvf Group Ltd | 3/9 | 3.84 | 0.6 | — |
| MGRX | MANGOCEUTICALS, INC. | 2/9 | 2.42 | — | — |
| BRTX | BioRestorative Therapies, Inc. | 3/9 | — | — | — |
About Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
FAQ
Is PGNY financially healthy?
Progyny, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PGNY pay a dividend?
No, Progyny, Inc. does not currently pay a dividend.
How profitable is PGNY?
In FY2025, Progyny, Inc. had a net margin of 4.5% and a return on equity of 11.3%.
Is PGNY overvalued or undervalued?
Progyny, Inc. trades at about 39.1× trailing earnings — below its 10-year norm (10-year range 36.7×–114.6×, median 61.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for PGNY?
The average Wall-Street price target for Progyny, Inc. is $30.00, about 18.0% above the recent price, from 11 analysts (consensus: strong buy).
Is PGNY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Progyny, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 38.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.